Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with Neurofibromatosis Type 1 By Ogkologos - July 1, 2025 318 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KOMET study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim MOST POPULAR FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head... July 18, 2025 Microplastics Can Be Detected In Human Organ Tissue August 20, 2020 How targeted screening can help the NHS save lives from lung... November 23, 2022 Survivorship and Immune Checkpoint Inhibitors July 21, 2020 Load more HOT NEWS Significant Benefits of Nivolumab Plus Cabozantinib Over Sunitinib in Previously Untreated... Evidence for the Utility of ctDNA Monitoring for Recurrence After CRC... Pregnant Mom Experiencing Severe Leg And Back Pain Diagnosed With Stage... Pioneer in Autism Diagnosis And Treatment Dies At 97
